
Diagnoly helps clinicians improve prenatal screening by providing real‑time AI analysis of fetal ultrasound to detect abnormalities and ensure complete exams. It builds Fetoly, a DeepTech B2B SaaS and medical device that uses AI and deep learning models integrated with ultrasound systems to provide on‑device, real‑time feedback during scans. Fetoly analyzes anatomical landmarks, detects over 100 fetal abnormalities, validates exam completeness against ISUOG guidelines, and automates repetitive measurements to increase consistency. The solution runs locally on mobile devices and remains compatible with major ultrasound platforms without requiring cloud services, preserving clinical data control. Diagnoly targets obstetricians and healthcare providers and holds FDA clearance for Fetoly‑Heart and CE marking for fetal heart and brain analysis.

Diagnoly helps clinicians improve prenatal screening by providing real‑time AI analysis of fetal ultrasound to detect abnormalities and ensure complete exams. It builds Fetoly, a DeepTech B2B SaaS and medical device that uses AI and deep learning models integrated with ultrasound systems to provide on‑device, real‑time feedback during scans. Fetoly analyzes anatomical landmarks, detects over 100 fetal abnormalities, validates exam completeness against ISUOG guidelines, and automates repetitive measurements to increase consistency. The solution runs locally on mobile devices and remains compatible with major ultrasound platforms without requiring cloud services, preserving clinical data control. Diagnoly targets obstetricians and healthcare providers and holds FDA clearance for Fetoly‑Heart and CE marking for fetal heart and brain analysis.
Product: Fetoly — on-device, real-time AI for fetal ultrasound quality assurance and landmark/abnormality detection
Regulatory: FDA clearance for Fetoly-Heart and CE marking for fetal heart and brain analysis
Business model: DeepTech B2B SaaS / medical device targeting obstetricians and healthcare providers
Funding: Seed round Apr 8, 2025 — €5.5M
HQ: Lyon, France
Prenatal screening quality assurance and fetal abnormality detection during obstetric ultrasound
2020
Medical Equipment Manufacturing
€5.5M
Seed round announced to accelerate development of AI prenatal-screening technology; participation from XAnge and existing investors including Les Business Angels des Grandes Écoles (BAdGE)
USD 7,048,095
“Includes participation from Mutuelles Impact, Newfund, XAnge, Les Business Angels des Grandes Écoles, BADGE and other angel / impact investors”
| Company |
|---|
Do you already have an experience in mobile development? Are you looking to be at the beginning of a new adventure and to make a larger impact in a smaller company?
Then this role is for you!
A small Deep Tech start-up headquartered in Lyon, France is looking for a developer, ready for the challenge of building an innovative architecture for medical software device deployed to tablets; Someone who is ready to redefine our software development and engineering practice, provide vision and leadership.
We are seeking candidates who have a strong background working within industrial software development.
Start-up activity
DIAGNOLY is a DeepTech start-up headquartered in Lyon, France. Our aim is to improve fetal screening and simplify obstetric ultrasound technique for the doctor. To do so, we develop an intelligent medical hardware device that will be connected to ultrasound machines. Analyzing the fetal examination in real time, our product will help doctors to detect the most complex fetal pathologies prenatally.
Increasing significantly prenatal detection rate of fetal pathologies, our product will reduce the risk of lifelong disabilities, handicap or lethal outcomes for concerned babies.
Your missions
Required knowledge and skills
Preferred
Work Location : On site
If you are interested do not hesitate to contact us at careers@diagnoly.com